A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3.
Youn Jin ChoiSoo Young HurTae-Jin KimSung Ran HongJae Kwan LeeChi-Heum ChoKi Seok ParkJung Won WooYoung Chul SungYou Suk SuhJong Sup ParkPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
GX-188E is an effective therapeutic vaccine against a cohort containing only CIN3 patients.
Keyphrases
- phase ii
- open label
- clinical trial
- high grade
- double blind
- phase iii
- end stage renal disease
- placebo controlled
- newly diagnosed
- phase ii study
- ejection fraction
- chronic kidney disease
- study protocol
- peritoneal dialysis
- prognostic factors
- radiation therapy
- patient reported outcomes
- randomized controlled trial
- cross sectional